Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drug tirzepatide aims to help people keep pounds off Long-Term

NCT ID NCT06047548

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug tirzepatide, given once weekly, can help people with obesity or overweight maintain weight loss they achieved during a prior diet period. About 441 participants took either tirzepatide or a placebo for 60 weeks. The goal was to see if the drug could prevent weight regain and improve related health issues like high blood pressure or sleep apnea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide
What this could lead to
If successful, tirzepatide could offer a long-term option to help people with obesity maintain weight loss and improve related health conditions.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. Weight regain after stopping the drug is possible, and side effects like nausea or diarrhea may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

441 people

The number who actually took part.

Started

Sep 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a Body Mass Index (BMI) of ≥30 kilogram/square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least 1 of the following weight related comorbidities: * Hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight (BW) Exclusion Criteria: * Have Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D), a history of ketoacidosis, or hyperosmolar state or coma. * Have a self-reported change in BW\>5 kilogram (kg) within 3 months prior to screening * Have a prior or planned surgical treatment for obesity, excluding liposuction or abdominoplasty if performed \>1 year prior to screening. * Have a history of chronic or acute pancreatitis * Have any of the following cardiovascular conditions within 3 months prior to week 0. * Acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, and hospitalization due to congestive heart failure (CHF) * family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years * Any lifetime history of a suicide attempt

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma, 73069, United States

  • Asha Clinical Research - Munster

    Hammond, Indiana, 46324, United States

  • Cahaba Research - Pelham

    Pelham, Alabama, 35124, United States

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814, United States

  • Encompass Clinical Research

    Spring Valley, California, 91978, United States

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa, 50265, United States

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • Oviedo Medical Research

    Oviedo, Florida, 32765, United States

  • Pinnacle Clinical Research

    San Antonio, Texas, 78229, United States

  • Prime Health and Wellness/SKYCRNG

    Fayette, Mississippi, 39069, United States

  • Rocky Mountain Clinical Research

    Idaho Falls, Idaho, 83404, United States

  • Rophe Adult and Pediatric Medicine/SKYCRNG

    Union City, Georgia, 30291, United States

  • Southern California Dermatology, Inc.

    Santa Ana, California, 92701, United States

  • Southern Endocrinology Associates

    Mesquite, Texas, 75149, United States

  • The University of Texas Health Science Center at Houston

    Bellaire, Texas, 77401, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research, Westlake

    Los Angeles, California, 90057, United States

  • WR-Clinsearch, LLC

    Chattanooga, Tennessee, 37397, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.